Webinar | July 30, 2025
Beyond DNA and RNA: Exposing What Sequencing Misses in Target ID and Biomarker Discovery
Get the Resource
Webinar - AAPS Webinar (Beyond DNA & RNA) - July 30, 2025
"*" indicates required fields
Now On Demand | Hosted by AAPS
Fueled by the rise of novel therapeutic modalities (ADCs, gene therapies, protein degraders, etc.) which have greatly expanded the druggable space, drug developers have significantly more opportunities to identify novel drug targets and proteins that modulate, or are modulated by, disease and drug response. As drug development moves beyond traditional known targets and biomarkers, mapping the full complexity of the human proteome – including non-canonical proteins in the “dark proteome” – is more critical than ever.
This webinar explores the gap between sequencing data and protein-level biology—and why tools that enable the direct measure of proteins and their variants are needed to effectively map the broader proteome, identify novel targets and biomarkers, and extract greater biological insight that drives better drug development decision-making
DNA and RNA sequencing have long served as surrogate measures for protein levels, grounded in the assumption that gene expression levels across the ~20,000 protein-coding genes in the human genome directly correlate to protein abundance. However, growing evidence shows that 1) canonical protein measures are often modestly correlated with mRNA levels, particularly in disease and treated states, and 2) RNA sequencing cannot capture post-translational modifications (PTMs) or non-canonical proteins which are not predicted by the human reference genome – although both PTMs and these “dark proteins” have been found to play critical roles in fundamental biological and disease processes.
During the webinar, you will hear about:
- The expanding opportunities for target identification and biomarker discovery in the human proteome, including protein isoforms as well as non-canonical proteins comprising the “dark proteome” which are not predicted by the human reference genome.
- The limitations of DNA and RNA sequencing to measure protein abundance
- Why next-generation proteomics, particularly using mass spectrometry, is essential to map the broader human proteome and identify robust targets to realize the therapeutic potential of emerging drugs
Complete the form to access the full recording!
Get the Resource
Webinar - AAPS Webinar (Beyond DNA & RNA) - July 30, 2025
"*" indicates required fields
